Gyre Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $9.9M | $17.9M | $-85.5M | $4.3M | $-87.9M | $-56.2M | $-55.2M | $-30.1M |
| Depreciation & Amortization | $2.5M | $1.5M | $1.1M | $1.1M | $290.0K | $138.0K | $146.0K | $149.0K |
| Depreciation | $2.0M | $1.3M | $1.0M | $900.0K | — | — | — | $100.0K |
| Amortization | $576.0K | $38.0K | $100.0K | $200.0K | — | — | — | — |
| Stock-Based Compensation | $7.2M | $831.0K | $7.3M | $13.4M | $3.4M | $3.6M | $3.2M | $2.6M |
| Net Cash from Operating Activities | $1.0M | $-3.6M | $25.9M | $10.7M | $-83.8M | $-55.0M | $-43.6M | $-28.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.2M | $2.3M | $8.5M | $5.0M | $839.0K | — | $64.0K | $376.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-474.0K | $-19.9M | $-19.8M | $-13.8M | $48.2M | $9.7M | $27.4M | $-71.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | $45.0M | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $24.4M | $2.1M | $2.5M | $-45.0M | $49.6M | $60.4M | $327.0K | $111.3M |
| Net Change in Cash | $25.3M | $-21.7M | $8.3M | $-5.0M | $14.0M | $15.0M | $-15.9M | $11.5M |
| Free Cash Flow | $-180.0K | $-6.0M | $17.4M | $5.7M | $-84.6M | — | $-43.7M | $-28.9M |